PharmaTher Holdings Ltd. believes the recent U.S. executive order on psychedelic treatments for serious mental illness may strengthen the strategic value of its ketamine portfolio, including its ketamine microneedle patch program, KetaVault partnership platform, and prior FDA-approved ketamine ANDA transaction.
The executive order, signed on April 18, 2026, emphasizes accelerated research, clinical trial participation, data sharing, and real-world evidence generation for psychedelic drugs. It calls for collaboration among the Department of Health and Human Services, the FDA, and the Department of Veterans Affairs to advance treatments for patients with severe and treatment-resistant mental health conditions. The order also calls for timely rescheduling of therapies that successfully complete late-stage clinical development and receive regulatory approval.
PharmaTher’s ketamine microneedle patch program represents what the company believes is a differentiated opportunity in the evolving regulatory environment. The company has previously completed an IND-enabling pharmacokinetic and tolerability study for its ketamine patch, positioning it as a patient-friendly ketamine delivery option across mental health, neurological, and pain disorders. A patch-based approach could offer strategic lifecycle value through controlled and sustained delivery, reduced treatment burden, and broader commercial flexibility.
Additionally, PharmaTher previously sold its U.S. ketamine ANDA to a sterile-injectables pharmaceutical company. The transaction could generate more than $25 million over time, subject to commercial performance and including milestone and profit-sharing payments. PharmaTher retains ownership of its broader ketamine portfolio, including ketamine-based programs for Parkinson’s disease, amyotrophic lateral sclerosis, and complex regional pain syndrome.
KetaVault, PharmaTher’s proprietary portal to ketamine data including INDs, CMC information, and clinical data, is available to pharmaceutical, biotech, academic, and government entities to accelerate partnerships and commercial planning across mental health, neurology, pain, and other ketamine opportunities.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.biospace.com/press-releases/pharmather-highlights-strategic-ketamine-opportunity-following-new-u-s-executive-order-on-psychedelic-treatments-for-serious-mental-illness